TY  - JOUR
AU  - Kaaks, Rudolf
AU  - Turzanski-Fortner, Renée
AU  - Hüsing, Anika
AU  - Barrdahl, Myrto
AU  - Hopper, Marika
AU  - Johnson, Theron Scot
AU  - Tjønneland, Anne
AU  - Hansen, Louise
AU  - Overvad, Kim
AU  - Fournier, Agnès
AU  - Boutron-Ruault, Marie-Christine
AU  - Kvaskoff, Marina
AU  - Dossus, Laure
AU  - Johansson, Mattias
AU  - Boeing, Heiner
AU  - Trichopoulou, Antonia
AU  - Benetou, Vassiliki
AU  - La Vecchia, Carlo
AU  - Sieri, Sabina
AU  - Mattiello, Amalia
AU  - Palli, Domenico
AU  - Tumino, Rosario
AU  - Matullo, Giuseppe
AU  - Onland-Moret, N Charlotte
AU  - Gram, Inger T
AU  - Weiderpass, Elisabete
AU  - Sánchez, Maria-Jose
AU  - Navarro Sanchez, Carmen
AU  - Duell, Eric J
AU  - Ardanaz, Eva
AU  - Larranaga, Nerea
AU  - Lundin, Eva
AU  - Idahl, Annika
AU  - Jirström, Karin
AU  - Nodin, Björn
AU  - Travis, Ruth C
AU  - Riboli, Elio
AU  - Merritt, Melissa
AU  - Aune, Dagfinn
AU  - Terry, Kathryn
AU  - Cramer, Daniel W
AU  - Anderson, Karen S
TI  - Tumor-associated autoantibodies as early detection markers for ovarian cancer? A prospective evaluation.
JO  - International journal of cancer
VL  - 143
IS  - 3
SN  - 0020-7136
CY  - Bognor Regis
PB  - Wiley-Liss
M1  - DKFZ-2018-01178
SP  - 515 - 526
PY  - 2018
AB  - Immuno-proteomic screening has identified several tumor-associated autoantibodies (AAb) that may have diagnostic capacity for invasive epithelial ovarian cancer, with AAbs to P53 proteins and cancer-testis antigens (CTAGs) as prominent examples. However, the early detection potential of these AAbs has been insufficiently explored in prospective studies. We performed ELISA measurements of AAbs to CTAG1A, CTAG2, P53 and NUDT11 proteins, for 194 patients with ovarian cancer and 705 matched controls from the European EPIC cohort, using serum samples collected up to 36 months prior to diagnosis under usual care. CA125 was measured using electrochemo-luminiscence. Diagnostic discrimination statistics were calculated by strata of lead-time between blood collection and diagnosis. With lead times ≤6 months, ovarian cancer detection sensitivity at 0.98 specificity (SE98) varied from 0.19 [95
LB  - PUB:(DE-HGF)16
C6  - pmid:29473162
C2  - pmc:PMC6019150
DO  - DOI:10.1002/ijc.31335
UR  - https://inrepo02.dkfz.de/record/136740
ER  -